# Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

> **NCT02466581** · PHASE4 · UNKNOWN · sponsor: **Karolinska Institutet** · enrollment: 25 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Sulphasalazine + Hydroxychloroquine OR Prednisolone
- **BIOLOGICAL:** Cimzia
- **BIOLOGICAL:** Orencia
- **BIOLOGICAL:** RoActemra

## Key facts

- **NCT ID:** NCT02466581
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02-03
- **Primary completion:** 2023-07-22
- **Final completion:** 2023-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02466581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02466581, "Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02466581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*